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Molecular Subtypes of Breast Cancers from
. Luminal types are cancers with a better prognosis in comparison to non-luminal types. Luminal breast cancer subtypes were found to predominate across racial/ethnic groups, while frequency of TN breast cancer progressively increases among white American, African-American, and Ghanaian/ Africans (Amirikia et al., 2011; Huo et al., 2009; Kurian et al., 2010; Stark et al., 2010) . As with other countries, breast cancer is a leading cause of morbidity and mortality in Myanmar women (Moore, 2014) . The aim of this study was to unveil the histopathological features and molecular subtypes in Myanmar breast cancer patients. We analyzed the clinicopathological characteristics and expression patterns of ER/PgR/HER2/Ki-67 using 91 female patients with breast cancer.
1
Materials and Methods
Study subjects
A total of 91 female patients diagnosed with breast cancer in the year 2015 were retrieved from pathology records at Myeik General Hospital (Myeik City, Myanmar) and Sakura Specialist Hospital (Yangon City, Myanmar). Clinicopathological data such as age, tumor size, lymph node and distant metastasis status were retrieved from the clinical and pathology records. All hematoxylin and eosin-stained sections were reviewed by two independent pathologists. Criteria defined by the World Health Organization (2012) were used for the histopathological diagnosis and classification of breast carcinoma. Nottingham combined histological grading system (Elston and Ellis, 1991) was used for tumor grading. American Joint Committee on Cancer staging system 8th edition was applied for tumor staging. The experimental protocol employed in this study was approved by the Ethics Committee of Okayama University (Japan) and the Ethics Review Committee of Department of Medical Research of Yangon City (Myanmar).
Immunohistochemical analysis
Immunohistochemistry was performed by using standardized automated techniques according to the manufacturer's protocol. Tissue sections were stained with antibodies ER (SP1), PgR (1E2), HER2 (4B5), Ki-67 (MIB-1), cytokeratin (CK) 5/6 (D5/16B4) and CK14 (LL002) using a Discovery XT autostainer with iVIEW DAB detection kit (Ventana Medical Systems, Tucson, Arizona). In case of ER/PgR, a staining > 1% of tumor cell nuclei was considered positive (Hammond et al., 2010) . HER2 was analyzed according to the American Society of Clinical Oncology and College of American Pathologists (Wolff et al., 2013) . A score of 0 to 1+ was considered as negative and 3+ as positive. Specimens with score of 2+ were analyzed by HER2 dual-color in situ hybridization at Hyogo Clinical Laboratory Cooperation (Himeji City, Japan). Ki-67 labeling index was defined as the percentage of positive nuclei, in which over 500 tumor cells were counted in each case. CK5/6 and CK14 were scored positive if any (weak or strong) cytoplasmic and/or membranous staining was observed. Breast cancers were classified into 5 molecular subtypes according to the St. Gallen International Expert Consensus 2011 (Goldhirsch et al., 2011) : luminal A; ER/PgR+/HER2-/ Ki-67<14%, luminal B (HER2-); ER/PgR+/HER2-/Ki-67≥14%, luminal B (HER2+); ER/PgR+/HER2+/any Ki-67 percentage, HER2; ER/PgR-/HER2+, and TN; ER/ PgR-/HER2-. TN subtype was further subdivided into basal-like type (ER/PgR-/HER2-with CK5/6+ and/or CK14+) and null type (ER/PgR-/HER2-/ CK5/6-/CK14-).
Statistical analysis
Statistical analyses were performed using SPSS software version 16.0. Fisher's exact test was used for data categorized into 2 × 2 contingency tables. The age, mitosis count and Ki-67 expression were reported using descriptive statistics and Mann Whitney U test to compare the mean of the variables. Two-sided tests were used for all analyses and p value <0.05 was considered as significant.
Results
Patient characteristics
Clinical data for the enrolled 91 female patients with breast cancer were shown in Table 1 . Ages ranged from 30 to 81 years with mean age of 51.3. Tumor sizes ranged from 1.5 cm to 7.2 cm with average size of 4.0 cm. Most of the cancers (94.5%) were invasive carcinoma of no special type (NST) with high histological grade (grade II; 46.2%, grade III; 53.8%). No grade I tumor was found. There were lymph node metastases in 57.1% of patients. The numbers of patients with stage I, II, III and IV were 6 (6.6%), 50 (54.9%), 31 (34.1%) and 4 (4.4%), respectively.
Molecular subtypes and immunophenotypic analyses
ER positive, PgR positive and HER2 positive cases were 57.1%, 37.4% and 28.6%, respectively. Molecular subtypes and clinicopathological features of 91 breast cancers were shown in Table 2 . The frequency of luminal A, a good prognostic subtype, was 11.0%. The most common subtype (39.6%) was luminal B (HER2-). Poor-prognosis subtypes, HER2 and TN subtypes, were and the associations between Ki-67 expression and clinicopathological features were investigated (Table 3) . Compared to Ki-67<14 as the reference, tumors with increased Ki-67 expression were associated with unfavorable features such as more mitoses and higher grade. Furthermore, younger patients, larger size (>2 cm), and higher stage were related to tumors with >30% Ki-67 expression. Interestingly, no difference was found in nodal status. ER/PgR negative tumors showed higher Ki-67 expression, whereas Ki-67 expression was not associated with HER2 overexpression. Overall, these data indicated that Ki-67 expression was significantly accompanied by advanced and aggressive cancer.
Discussion
The present study reported the histopathological characteristics of Myanmar breast cancer patients. We analyzed 91 cases, in which 93% of the breast cancers were larger than 2 cm. There was no histological grade I and 53.8% of the cancers were grade III. Over half of the patients (57.1%) had lymph node involvement at the time of diagnosis. These findings may result from the lack of early detection system in Myanmar. It is also possible that 22.0 and 20.9%, respectively. Among TN subtypes, 11 cases (12.1%) were basal-like type (7 cases; CK5/6+ and CK14+, 4 cases; CK5/6-and CK14+) and 8 cases (8.8%) were null type. Compared to luminal A as the reference, tumors larger than 2 cm were more in HER2 subtype. TN-basal-like also tended to be larger than 2 cm although it was not statistically significant. Histological grade III (poorly differentiated) was more frequently found in non-luminal A subtypes, particularly in TN-basal-like and HER2, with more advanced stages at diagnosis (stage II, III and IV). As compared to luminal A, HER2 subtype tended to metastasize to lymph nodes, although it was not statistically significant ( Table 2 ). The mean Ki-67 index of all 91 cases was 33.9% (mean ± SD, 33.9 ± 19.2) and the median score was 28% (range; 4%-90%). In the subtype analyses, the mean Ki-67 expression was increased in the following order; luminal A < luminal B < HER2 < TN (null<basal-like), which corresponded well to the increased number of mitoses (Table 2) .
A s s o c i a t i o n b e t w e e n K i -6 7 e x p re s s i o n a n d clinicopathological features
The Ki-67 expression was divided into 3 levels (<14; 12.1%, 14-30; 40.7%, >30; 47.2%) Myanmar breast cancers are aggressive in nature.
Revealing the hormonal receptor status and HER2 and Ki-67 expression is useful not only for treatment strategy but for estimating the patient prognosis (malignant potential) (Goldhirsch et al., 2011) . Generally, overall survival of breast cancers by subtypes from good-to poor-prognosis is: luminal A, luminal B, HER2 and TN (Hennigs et al., 2016) . ER positive breast cancers are most frequent in western countries. In the United States, most (73%) breast cancers are luminal A and luminal B (HER2-) subtypes. About 10% of breast cancers are luminal B (HER2+), 4% are HER2 and 12% are TN (Howlader et al., 2014) . Table 4 shows the summary of the percent composition of molecular subtypes of breast cancers in western countries, South Asia, South-east Asia and East Asia. In Asian countries except China, HER2 and TN subtypes are prevailing compared to those in western countries. In the present Myanmar study, unfavorable molecular subtypes, HER2 and TN, were responsible for 42.9% of all cancers, suggesting that most breast cancers in Myanmar are aggressive in nature. Interestingly, the composition of molecular subtypes in Myanmar (this study) is comparable to that in a Vietnamese study (Thang et al., 2015) , with low luminal A and B and in contrast high HER2 and TN. These similarities may be related to some genetic or biological connections, as well as comparable environmental factors.
In conclusion, the present study for the first time highlights the clinicopathological features of breast cancers from Myanmar women, which provide valuable information for the breast cancer control. Approximately 80% of the breast cancers were positive for either hormone receptor or HER2. Hormone therapy and anti-HER2 therapy may offer significant benefits to the Myanmar breast cancer patients, when used properly. Moreover, it is essential to establish early detection of breast cancer: education to promote early diagnosis and screening. Early detection alleviates the advanced breast cancer and increases the opportunities for successful treatment.
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